Protalix BioTherapeutics Reports Third Quarter 2019 Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Protalix BioTherapeutics (PLX) Misses Q3 EPS by 10c
November 7, 2019 6:53 AM ESTProtalix BioTherapeutics (NYSE: PLX) reported Q3 EPS of ($0.13), $0.10 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $12.09 million versus the consensus estimate of $11.6 million.
"This has been a consequential quarter for Protalix during which we continued... More
